Bicycle Therapeutics Q2 2026: $50.3M Loss, Bayer Collaboration Terminated, Pipeline Reprioritized
BCYC is trading near its 52-week low of $3.85 (0.8% below the low).
Summary
Bicycle Therapeutics posted a $50.3M Q2 loss with $510.1M in cash. The Bayer collaboration was terminated, triggering a $33.2M revenue recognition in Q3. The strategic reprioritization is underway, with R&D costs falling and the pipeline focused on nuzefatide pevedotin.
Key Events · Earnings and Guidance · BCYC
-
Q2 2026 Financial Results
A net loss of $50.3 million was recorded on collaboration revenue of just $0.6 million. Cash and cash equivalents stood at $510.1 million as of June 30, 2026, a level expected to fund operations for at least the next 12 months.
-
Bayer Collaboration Terminated
In July 2026, Bayer gave notice of termination, effective September 2026. The remaining $33.2 million in deferred revenue will be recognized in Q3 2026, but future collaboration revenue from Bayer is eliminated.
-
Strategic Reprioritization Progress
The 30% workforce reduction remains on track, with $5.5 million in severance charges recognized in the first half of 2026. Annual operating expenses are expected to decrease by approximately 50%. Zelenectide pevedotin has been deprioritized, shifting focus to nuzefatide pevedotin and next-generation Bicycle conjugates.
-
Pipeline Update
A Phase II trial of nuzefatide pevedotin in pancreatic cancer has been initiated, with the first patient dosed in April 2026. BT1702 (MT1-MMP BRC) is in IND-enabling studies. Development of BT7480 will be discontinued internally, while partnership opportunities are explored.
Analysis · BCYC · Life Sciences
A $50.3 million net loss marked Bicycle Therapeutics' Q2 2026, though cash reserves of $510.1 million extend the runway through at least mid-2027. The quarter's defining event was the termination of the Bayer collaboration — a move that will accelerate $33.2 million in deferred revenue recognition into Q3 but removes a key partnership. Meanwhile, the strategic reprioritization is taking hold: R&D spending dropped sharply as the zelenectide program was deprioritized and a 30% workforce reduction progressed. The focus now shifts to nuzefatide pevedotin in pancreatic cancer and next-generation radioconjugates. While the cash position is solid, the loss of collaboration revenue and the need to advance a narrower pipeline raise the stakes for clinical execution.
At the time of this filing, BCYC was trading at $3.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $269.1M. The 52-week trading range was $3.85 to $9.16. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.